Trade Biodesix, Inc. - BDSX CFD

Add to favourite

1.2368

2.49%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.0164

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Biodesix Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	1.2068
Open*	1.1768
1-Year Change*	-36.29%
Day's Range*	1.1768 - 1.2368
52 wk Range	1.03-2.53
Average Volume (10 days)	97.00K
Average Volume (3 months)	1.62M
Market Cap	176.43M
P/E Ratio	-100.00K
Shares Outstanding	90.48M
Revenue	44.03M
EPS	-0.90
Dividend (Yield %)	N/A
Beta	-100.00K
Next Earnings Date	Mar 4, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	1.2368	0.0600	5.10%	1.1768	1.2368	1.1768
Apr 17, 2024	1.2068	0.0000	0.00%	1.2068	1.2068	1.1768
Apr 16, 2024	1.2268	0.0200	1.66%	1.2068	1.2268	1.2068
Apr 15, 2024	1.2468	0.0700	5.95%	1.1768	1.2468	1.1768
Apr 12, 2024	1.2268	-0.0100	-0.81%	1.2368	1.2468	1.1968
Apr 11, 2024	1.2368	0.0400	3.34%	1.1968	1.2468	1.1768
Apr 10, 2024	1.2268	-0.0100	-0.81%	1.2368	1.2368	1.1368
Apr 9, 2024	1.2568	-0.1500	-10.66%	1.4068	1.4068	1.1968
Apr 8, 2024	1.3868	0.0300	2.21%	1.3568	1.4368	1.2868
Apr 5, 2024	1.3768	0.1300	10.43%	1.2468	1.4368	1.2068
Apr 4, 2024	1.4968	-0.0200	-1.32%	1.5168	1.5168	1.4668
Apr 3, 2024	1.5368	0.0800	5.49%	1.4568	1.5368	1.4468
Apr 2, 2024	1.4768	0.0100	0.68%	1.4668	1.4768	1.4068
Apr 1, 2024	1.4468	0.0200	1.40%	1.4268	1.4468	1.3668
Mar 28, 2024	1.4268	-0.0100	-0.70%	1.4368	1.4468	1.4168
Mar 27, 2024	1.4168	-0.0300	-2.07%	1.4468	1.4468	1.3968
Mar 26, 2024	1.4268	-0.0600	-4.04%	1.4868	1.4868	1.4068
Mar 25, 2024	1.4368	0.0300	2.13%	1.4068	1.4768	1.4068
Mar 22, 2024	1.3568	0.0100	0.74%	1.3468	1.3568	1.3068
Mar 21, 2024	1.3468	-0.0600	-4.26%	1.4068	1.4168	1.3468

Biodesix, Inc. Events

Time (UTC)	Country	Event
Thursday, May 9, 2024
Time (UTC) 10:59	Country US	Event Q1 2024 Biodesix Inc Earnings Release Q1 2024 Biodesix Inc Earnings Release Forecast - Previous -
Wednesday, May 22, 2024
Time (UTC) 19:00	Country US	Event Biodesix Inc Annual Shareholders Meeting Biodesix Inc Annual Shareholders Meeting Forecast - Previous -
Monday, August 5, 2024
Time (UTC) 10:59	Country US	Event Q2 2024 Biodesix Inc Earnings Release Q2 2024 Biodesix Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	38.212	54.506	45.557	24.552	20.432
Revenue	38.212	54.506	45.557	24.552	20.432
Cost of Revenue, Total	14.154	30.518	21.998	6.074	4.406
Gross Profit	24.058	23.988	23.559	18.478	16.026
Total Operating Expense	95.78	93.148	68.491	51.293	44.095
Selling/General/Admin. Expenses, Total	58.458	47.958	32.328	30.637	25.899
Research & Development	13.102	12.789	10.818	10.468	8.188
Unusual Expense (Income)	7.062	-2.298		3.451	1.739
Other Operating Expenses, Total	0	1.622	0.818	0.663	3.863
Operating Income	-57.568	-38.642	-22.934	-26.741	-23.663
Interest Income (Expense), Net Non-Operating	-8.072	-4.508	-7.586	-2.953	-2.892
Other, Net	0.193	-0.009	-0.83	-1.032	0.389
Net Income Before Taxes	-65.447	-43.159	-31.35	-30.726	-26.166
Net Income After Taxes	-65.447	-43.159	-31.35	-30.726	-26.166
Net Income Before Extra. Items	-65.447	-43.159	-31.35	-30.726	-26.166
Net Income	-65.447	-43.159	-31.35	-30.726	-26.166
Income Available to Common Excl. Extra. Items	-65.447	-43.159	-31.35	-30.726	-26.166
Income Available to Common Incl. Extra. Items	-65.447	-43.159	-31.35	-30.726	-26.166
Diluted Net Income	-65.447	-43.159	-31.35	-30.726	-26.166
Diluted Weighted Average Shares	42.103	27.365	26.5615	26.2541	26.2541
Diluted EPS Excluding Extraordinary Items	-1.55445	-1.57716	-1.18028	-1.17033	-0.99665
Dividends per Share - Common Stock Primary Issue				0	0
Diluted Normalized EPS	-1.38672	-1.66114	-1.14948	-1.03889	-0.93041
Depreciation / Amortization	3.004	2.559	2.529

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	11.872	9.056	9.607	11.107	10.95
Revenue	11.872	9.056	9.607	11.107	10.95
Cost of Revenue, Total	3.238	3.169	3.306	3.633	3.98
Gross Profit	8.634	5.887	6.301	7.474	6.97
Total Operating Expense	22.799	25.429	27.474	21.769	25.528
Selling/General/Admin. Expenses, Total	16.651	18.989	16.626	15.114	15.235
Research & Development	2.91	3.251	3.565	2.97	3.361
Unusual Expense (Income)	0	0.02	3.977	0.052	2.952
Operating Income	-10.927	-16.373	-17.867	-10.662	-14.578
Interest Income (Expense), Net Non-Operating	-2.43	-2.391	-2.55	-3.039	-1.346
Other, Net	0.001	0.062	0.079	0.002	0.1
Net Income Before Taxes	-13.356	-18.702	-20.338	-13.699	-15.824
Net Income After Taxes	-13.356	-18.702	-20.338	-13.699	-15.824
Net Income Before Extra. Items	-13.356	-18.702	-20.338	-13.699	-15.824
Net Income	-13.356	-18.702	-20.338	-13.699	-15.824
Income Available to Common Excl. Extra. Items	-13.356	-18.702	-20.338	-13.699	-15.824
Income Available to Common Incl. Extra. Items	-13.356	-18.702	-20.338	-13.699	-15.824
Diluted Net Income	-13.356	-18.702	-20.338	-13.699	-15.824
Diluted Weighted Average Shares	78.506	77.765	57.553	40.448	39.239
Diluted EPS Excluding Extraordinary Items	-0.17013	-0.24049	-0.35338	-0.33868	-0.40327
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.17013	-0.24024	-0.28428	-0.3374	-0.32804
Other Operating Expenses, Total			0	0	0

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	53.334	43.613	86.14	12.7	9.913
Cash and Short Term Investments	43.088	32.712	62.126	5.286	5.914
Cash & Equivalents	43.088	32.712	62.126	5.286	5.914
Total Receivables, Net	5.065	3.656	15.304	5.292	1.892
Accounts Receivable - Trade, Net	5.065	3.656	15.304	5.292	1.892
Other Current Assets, Total	5.181	7.245	8.71	2.122	2.107
Total Assets	92.906	76.097	121.07	41.633	39.057
Property/Plant/Equipment, Total - Net	8.821	4.179	3.178	2.12	1.388
Property/Plant/Equipment, Total - Gross	15.839	10.928	9.902	8.506	6.956
Accumulated Depreciation, Total	-7.018	-6.749	-6.724	-6.386	-5.568
Goodwill, Net	15.031	15.031	15.031	11.631	10.804
Intangibles, Net	9.797	11.617	13.26	15.092	16.852
Other Long Term Assets, Total	5.923	1.657	3.461	0.09	0.1
Total Current Liabilities	22.839	28.96	32.125	22.6	4.468
Accounts Payable	1.685	1.662	8.964	1.717	0.886
Accrued Expenses	7.446	4.899	4.69	1.899	1.568
Notes Payable/Short Term Debt	0	0	0	12.045	0
Other Current Liabilities, Total	13.659	22.38	6.631	6.939	2.014
Total Liabilities	72.3	56.37	79.904	76.213	53.125
Total Long Term Debt	25.004	9.993	15.926	23.812	23.099
Long Term Debt	25.004	9.993	15.926	23.812	23.099
Other Liabilities, Total	24.457	17.417	31.853	29.801	25.558
Total Equity	20.606	19.727	41.166	-34.58	-14.068
Redeemable Preferred Stock	0	0	0	193.959	183.962
Common Stock	0.078	0.031	0.027	0.001	0.001
Additional Paid-In Capital	387.948	321.669	299.953	2.324	2.107
Retained Earnings (Accumulated Deficit)	-367.42	-301.973	-258.814	-230.864	-200.138
Total Liabilities & Shareholders’ Equity	92.906	76.097	121.07	41.633	39.057
Total Common Shares Outstanding	77.6144	30.7896	26.5615	26.2541	26.2541
Current Port. of LT Debt/Capital Leases	0.049	0.019	11.84	0

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	28.886	25.245	34.784	53.334	24.118
Cash and Short Term Investments	19.841	17.409	25.275	43.088	15.175
Cash & Equivalents	19.841	17.409	25.275	43.088	15.175
Total Receivables, Net	5.777	4.119	4.901	5.065	4.449
Accounts Receivable - Trade, Net	5.777	4.119	4.901	5.065	4.449
Other Current Assets, Total	3.268	3.717	4.608	5.181	4.494
Total Assets	86.786	77.623	80.793	92.906	63.198
Property/Plant/Equipment, Total - Net	27.488	21.488	15.291	8.821	7.734
Property/Plant/Equipment, Total - Gross	35.364	29.079	22.599	15.839	15.151
Accumulated Depreciation, Total	-7.876	-7.591	-7.308	-7.018	-7.417
Goodwill, Net	15.031	15.031	15.031	15.031	15.031
Intangibles, Net	8.416	8.871	9.311	9.797	10.223
Other Long Term Assets, Total	6.965	6.988	6.376	5.923	6.092
Total Current Liabilities	32.649	27.951	22.098	22.839	37.415
Accounts Payable	2.904	3.501	1.563	1.685	2.1
Accrued Expenses	5.68	6.687	6.027	7.446	6.017
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	0.05	0.05	0.05	0.049	14.334
Other Current Liabilities, Total	24.015	17.713	14.458	13.659	14.964
Total Liabilities	88.232	84.616	76.243	72.3	66.101
Total Long Term Debt	24.95	24.658	25.084	25.004	4.88
Long Term Debt	24.95	24.658	25.084	25.004	4.88
Other Liabilities, Total	30.633	32.007	29.061	24.457	23.806
Total Equity	-1.446	-6.993	4.55	20.606	-2.903
Redeemable Preferred Stock	0	0	0	0	0
Common Stock	0.088	0.079	0.078	0.078	0.041
Additional Paid-In Capital	408.893	392.406	390.594	387.948	344.138
Retained Earnings (Accumulated Deficit)	-410.427	-399.478	-386.122	-367.42	-347.082
Total Liabilities & Shareholders’ Equity	86.786	77.623	80.793	92.906	63.198
Total Common Shares Outstanding	88.3158	78.6107	77.9794	77.6144	41.1855

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-65.447	-43.159	-31.35	-30.726	-26.166
Cash From Operating Activities	-44.972	-28.223	-21.366	-21.726	-17.677
Cash From Operating Activities	3.597	3.178	2.903	2.793	1.74
Non-Cash Items	20.316	7.167	11.882	7.852	6.496
Changes in Working Capital	-3.438	4.591	-4.801	-1.645	0.253
Cash From Investing Activities	-3.534	-2.547	-2.927	-1.872	-0.617
Capital Expenditures	-3.534	-2.547	-2.177	-1.416	-0.617
Other Investing Cash Flow Items, Total		0	-0.75	-0.456	0
Cash From Financing Activities	58.882	1.262	81.131	22.972	19.032
Financing Cash Flow Items	-17.423	-0.5	-8.249	-0.119	-0.283
Issuance (Retirement) of Stock, Net	59.807	17.112	73.34	10.047	8.55
Issuance (Retirement) of Debt, Net	16.498	-15.35	16.04	13.044	10.765
Net Change in Cash	10.376	-29.508	56.838	-0.626	0.738
Cash Interest Paid	1.009	1.676	1.844

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-18.702	-65.447	-45.109	-31.41	-15.586
Cash From Operating Activities	-7.686	-44.972	-33.024	-22.693	-13.099
Cash From Operating Activities	0.785	3.597	2.699	1.806	0.908
Non-Cash Items	4.555	20.316	13.452	8.61	2.674
Changes in Working Capital	5.676	-3.438	-4.066	-1.699	-1.095
Cash From Investing Activities	-7.706	-3.534	-1.547	-0.732	-0.352
Capital Expenditures	-7.706	-3.534	-1.547	-0.732	-0.352
Other Investing Cash Flow Items, Total
Cash From Financing Activities	-2.421	58.882	17.034	19.299	-2.834
Financing Cash Flow Items	-2.415	-17.423	-11.145	-9.005	-4.6
Issuance (Retirement) of Stock, Net	0.006	59.807	18.115	16.227	1.674
Issuance (Retirement) of Debt, Net	-0.012	16.498	10.064	12.077	0.092
Net Change in Cash	-17.813	10.376	-17.537	-4.126	-16.285
Cash Interest Paid	1.032	1.009	0.473	0.344	0.223
Cash Taxes Paid	0		0	0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Biodesix, Inc. Company profile

About Biodesix Inc

Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology. The Company’s product Biodesix Lung Reflex integrates genomic and proteomic blood-based results to reveal both sides of lung cancer. Its GeneStrat test offers blood-based mutation results within 72 hours for patients with non-small cell lung cancer (NSCLC). Its VeriStrat testing provides blood-based predictive and prognostic proteomic information with (NSCLC) who test negative for estimated glomerular filtration rate (EGFR) mutations (EGFR wild-type) or whose EGFR mutation status is unknown.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Biodesix Inc revenues increased 20% to $54.5M. Net loss increased 38% to $43.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Sales, marketing, general and administ increase of 49% to $43.6M (expense), Research and development - Balancing v increase of 19% to $12.2M (expense).

Industry:

Medical & Diagnostic Laboratories

Suite 100
2970 Wilderness Place
BOULDER
COLORADO 80301
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024